Amundi boosted its stake in shares of Bath & Body Works, Inc. (NYSE:BBWI - Free Report) by 382.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 174,951 shares of the company's stock after buying an additional 138,664 shares during the period. Amundi owned about 0.08% of Bath & Body Works worth $4,872,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. increased its position in shares of Bath & Body Works by 7.6% in the first quarter. T. Rowe Price Investment Management Inc. now owns 11,016,767 shares of the company's stock worth $334,029,000 after acquiring an additional 781,681 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Bath & Body Works by 14,732.0% in the 1st quarter. Victory Capital Management Inc. now owns 6,798,108 shares of the company's stock worth $206,119,000 after purchasing an additional 6,752,274 shares during the period. GMT Capital Corp grew its position in Bath & Body Works by 7.3% during the 1st quarter. GMT Capital Corp now owns 3,737,700 shares of the company's stock worth $113,327,000 after purchasing an additional 255,600 shares in the last quarter. Fuller & Thaler Asset Management Inc. raised its stake in Bath & Body Works by 115.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 3,680,104 shares of the company's stock valued at $111,581,000 after purchasing an additional 1,973,679 shares during the period. Finally, Northern Trust Corp raised its stake in Bath & Body Works by 12.7% during the 1st quarter. Northern Trust Corp now owns 2,389,781 shares of the company's stock valued at $72,458,000 after purchasing an additional 269,508 shares during the period. 95.14% of the stock is owned by hedge funds and other institutional investors.
Bath & Body Works Trading Down 1.5%
NYSE BBWI traded down $0.39 during trading on Tuesday, hitting $26.07. 8,220,160 shares of the company traded hands, compared to its average volume of 6,764,256. Bath & Body Works, Inc. has a 12 month low of $24.94 and a 12 month high of $41.87. The business has a fifty day simple moving average of $30.03 and a 200 day simple moving average of $29.96. The company has a market capitalization of $5.38 billion, a P/E ratio of 7.74, a PEG ratio of 0.90 and a beta of 1.49.
Bath & Body Works (NYSE:BBWI - Get Free Report) last released its quarterly earnings results on Thursday, August 28th. The company reported $0.37 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.37. Bath & Body Works had a negative return on equity of 48.43% and a net margin of 9.88%.The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.55 billion. During the same quarter in the prior year, the company posted $0.37 EPS. The firm's revenue was down .8% on a year-over-year basis. Bath & Body Works has set its Q3 2025 guidance at 0.370-0.45 EPS. FY 2025 guidance at 3.350-3.600 EPS. Equities research analysts predict that Bath & Body Works, Inc. will post 3.3 EPS for the current fiscal year.
Bath & Body Works Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, September 5th. Shareholders of record on Friday, August 22nd were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 3.1%. The ex-dividend date was Friday, August 22nd. Bath & Body Works's dividend payout ratio (DPR) is 23.74%.
Analyst Upgrades and Downgrades
Several analysts have recently commented on BBWI shares. The Goldman Sachs Group decreased their target price on Bath & Body Works from $44.00 to $43.00 and set a "buy" rating for the company in a research report on Friday, May 30th. Morgan Stanley lowered their target price on Bath & Body Works from $19.00 to $18.00 and set an "overweight" rating on the stock in a research note on Friday. Wall Street Zen lowered shares of Bath & Body Works from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Telsey Advisory Group restated an "outperform" rating and set a $38.00 price target on shares of Bath & Body Works in a report on Thursday, August 28th. Finally, UBS Group dropped their price objective on shares of Bath & Body Works from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, August 29th. Twelve analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $39.69.
Check Out Our Latest Stock Report on Bath & Body Works
Bath & Body Works Profile
(
Free Report)
Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.
Further Reading

Before you consider Bath & Body Works, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bath & Body Works wasn't on the list.
While Bath & Body Works currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.